Navigation Links
Hot on the trail of metabolic diseases and resistance to antibiotics
Date:3/28/2012

ABC transporters are membrane proteins that actively pump a wealth of molecules across the membrane. Over 40 different ABC transporters perform vital functions in humans. Genetic defects in ABC transporters can trigger metabolic diseases such as gout, neonatal diabetes or cystic fibrosis, and certain ABC transporters also cause resistance to a wide range of drugs. In tumor cells, increased amounts of ABC transporters that pump chemotherapeutic substances out of the cell are often produced, thus rendering anticancer drugs ineffective. Analogous mechanisms play a key role in many pathogenic bacteria: ABC transporters carry antibiotics out of the cell multi-resistant bacteria are the result.

Despite their major importance in biology and medicine, so far the atomic structure of only a few ABC transporters has been decoded. Now, under the supervision of Markus Seeger and Professor Markus Grtter, PhD student Michael Hohl and senior scientist Christophe Briand have succeeded in cracking the atomic structure of the new ABC transporter "TM287/288".

Illuminating asymmetry

The membrane protein originates from a thermophilic bacterium. Compared to structures already known, "TM287/288" has two different protein chains that assemble into a heterodimer. About half of the 40 human ABC transporters are heterodimers. "The asymmetries discovered enable us to consider the role of ABC transporters in a new light," explains Seeger. "In the longer term, our results could help develop new medication against multi-resistant bacteria or tumors that are difficult to treat. They also make new approaches to curing or alleviating hereditary diseases possible," concludes Grtter.


'/>"/>
Contact: Dr. Markus Seeger
m.seeger@bioc.uzh.ch
41-446-355-552
University of Zurich
Source:Eurekalert

Page: 1

Related biology news :

1. On the trail of a targeted therapy for blood cancers
2. Lead-flapping objects experience less wind resistance than their trailing counterparts
3. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
4. Trailblazing rural community shows green heating oil a viable option
5. Lake-bed trails tell ancient fish story
6. Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award
7. Following trail of cell death in epilepsy patients to find ways to preserve brain health
8. Researchers on the trail of a treatment for cancer of the immune system
9. Limits for mountain trail use identified
10. Following the trail of conservation successes
11. On the trail of biomarkers and signalling substances with major instrumentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ... a therapeutic intervention. Tests based on biomarkers have ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ... Market by Technology, Application & by Products - Global ... The global genotyping market is expected to reach ... at a CAGR of 22.3% during the forecast period ... be attributed to the availability of a range of ...
(Date:6/2/2015)... PAULO , June 2, 2015   Hospira, ... in biosimilars, today announced that its partner, Celltrion – a ... – the National Health Surveillance Agency in ... biosimilar monoclonal antibody approved for use in ... Hospira. Hospira also markets and sells biosimilar infliximab in ...
(Date:6/2/2015)... June 02, 2015 “Stem Cell Therapy to ... mainstream, and it is used often as an adjunct to ... practitioners are not yet aware or comfortable enough with the ... is most often reserved for the last resort cases - ... can barely lift a paw to get around. It is ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery technology into ... to help prevent and treat flu-type symptoms resulting from influenza-like ... , , The unique attributes of the ...
... , ATLANTA, Sept. 21 CryoLife, Inc. (NYSE: ... to suburban Atlanta this week for the two-day Ross Summit ... of the Ross Procedure and to practice the technical nuances required to perform ... The Ross Procedure is a type of specialized aortic valve surgery in ...
... Mass., Sept. 21 Merrimack Pharmaceuticals, Inc., announced today that ... President, Development. Dr. Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) ... oncology. Dr. Niyikiza has extensive drug development experience with ... pharmaceutical industry in which he has led ten New Drug ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 2Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 4Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 5Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2
Eagle's Ham's amino acids; EHAA...
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
... System more than doubles the benefits of ... fast analysis cycles of the standard binary ... in tandem mode. Difficult separations are dramatically ... or heartcut configurations, on-line sample preparation is ...
... The PerkinElmer kit provides reagents for ... in serum and plasma samples using a ... samples are then neutralized and transferred to ... highly specific mouse monoclonal antibody to HIV-1 ...
Biology Products: